ABAntonio Broncano-Lavado

Antonio Broncano-Lavado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonio Broncano-Lavado has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria

    by Abrar Senhaji-Kacha, Arij Akir, Antonio Broncano-Lavado, Jaime Esteban

    Introduction. Mycobacterium avium complex (MAC) and Mycobacterium abscessus are a group of nontuberculous mycobacteria (NTM) that have been described as human pathogens. Their ability to develop biofilms in tissues and medical devices is one of the most important pathogenicity factors, with important implications in diagnosis and treatment. Macrolides are usually considered one of the bases of this treatment. Methods. Here we have studied the biofilm prevention concentration (BPC) of 16 strains (n=16) with clarithromycin to avoid the biofilm development by these NTM. Results. In this study, all M. abscessus strains have similar BPC, while MAC strains showed different values. For MAC the concentrations ranged between 1-16 mg/L, while for M. abscessus the concentration was 32 mg/L for all strains except one that was 64 mg/L. Conclusions. These results open the possibility of using macrolides for the prevention of biofilm development in patients with a risk of developing NTM disease.


  • Open Access

    Alternatives to Antibiotics against Mycobacterium abscessus

    by Antonio Broncano-Lavado, Abrar Senhaji-Kacha, Guillermo Santamaría-Corral, Jaime Esteban, Meritxell García-Quintanilla

    Mycobacterium abscessus complex is extremely difficult to treat. Intrinsic and acquired bacterial resistance makes this species one of the most challenging pathogens and treatments last from months to years, associated with potential risky antibiotic toxicity and a high number of failures. Nonantibiotic antimicrobial agents against this microorganism have recently been studied so as to offer an alternative to current drugs. This review summarizes recent research on different strategies such as host modulation using stem cells, photodynamic therapy, antibiofilm therapy, phage therapy, nanoparticles, vaccines and antimicrobial peptides against M. abscessus both in vitro and in vivo.


  • Open Access

    Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens

    by Antonio Broncano-Lavado, Guillermo Santamaría-Corral, Jaime Esteban, Meritxell García-Quintanilla

    The increase of multiresistance in bacteria and the shortage of new antibiotics in the market is becoming a major public health concern. The World Health Organization (WHO) has declared critical priority to develop new antimicrobials against three types of bacteria: carbapenem-resistant A. baumannii, carbapenem-resistant P. aeruginosa and carbapenem-resistant and ESBL-producing Enterobacteriaceae. Phage therapy is a promising alternative therapy with renewed research in Western countries. This field includes studies in vitro, in vivo, clinical trials and clinical cases of patients receiving phages as the last resource after failure of standard treatments due to multidrug resistance. Importantly, this alternative treatment has been shown to be more effective when administered in combination with antibiotics, including infections with biofilm formation. This review summarizes the most recent studies of this strategy in animal models, case reports and clinical trials to deal with infections caused by resistant A. baumannii, K. pneumoniae, E. coli, and P. aeruginosa strains, as well as discusses the main limitations of phage therapy.


  • Open Access

    Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late

    by Miguel Górgolas Hernández-Mora, Alfonso Cabello Úbeda, Laura Prieto Pérez, Felipe Villar Álvarez, Beatriz Álvarez Álvarez, María Jesús Rodríguez Nieto, Irene Carrillo Acosta, Itziar Fernández Ormaechea, Aws Waleed Mohammed Al-Hayani, Pilar Carballosa, et al.

    Summary: Introduction: Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there is no data about the best moment for its administration along the course of the disease. Methods: We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary endpoint was intubation or death after 24 hours of its administration. Patients received at least one dose of 400 mg intravenous tocilizumab during March 8-2020, through April 20-2020. Findings: A total of 207 patients were studied and 186 analysed. The mean age was 65 years and 68% were male. A co-existing condition was present in 68 % of cases. At baseline, 114 (61%) required oxygen support with FiO2 >0.5 % and 72 (39%) ≤0.5%. Early administration of tocilizumab, when the need of oxygen support was still below FiO2 ≤0.5%, was significantly more effective than given it in advanced stages (FiO2 >0.5 %), achieving lower rates of intubation or death (13% vs 37% repectively, p<0·001). Interpretation: The benefit of tocilizumab in severe SARS-Cov-2 pneumonia is only expected when it is administrated before the need of high oxygen support. Funding: None.